A phase III study of radiation therapy plus carmustine with or without recombinant interferon-? in the treatment of patients with newly diagnosed high-grade glioma

Abstract

IFN-alpha does not appear to improve time to disease progression or overall survival in patients with high-grade glioma and appears to add significantly to toxicity. The baseline MMSE score may serve as an independent prognostic factor and warrants further investigation.